PriceTargets.com logo

Molecular Templates - MTEM Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.83
  • Forecasted Upside: 542.64 %
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.60 As of 11/28/2022 02:37 PM ET
▲ +0.0059 (1.00%)

This chart shows the closing price for MTEM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Molecular Templates Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MTEM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MTEM

Analyst Price Target is $3.83
▲ +542.64% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Molecular Templates in the last 3 months. The average price target is $3.83, with a high forecast of $9.00 and a low forecast of $1.00. The average price target represents a 542.64% upside from the last price of $0.60.

This chart shows the closing price for MTEM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 investment analysts is to hold stock in Molecular Templates. This rating has held steady since May 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/6/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/4/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/3/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/30/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/29/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/28/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/11/2022BarclaysLower TargetOverweight$4.50 ➝ $1.00Low
5/27/2022Bank of AmericaDowngradeBuy ➝ Underperform$1.50High
5/13/2022Stifel NicolausLower Target$11.00 ➝ $9.00Medium
3/30/2022BarclaysLower TargetOverweight$8.00 ➝ $4.50Medium
12/3/2021BarclaysReiterated RatingBuy$8.00N/A
4/21/2021Bank of AmericaInitiated CoverageBuy$12.00High
4/15/2021OppenheimerLower TargetOutperform$18.00 ➝ $13.00Medium
4/6/2021Jefferies Financial GroupBoost Target$18.00 ➝ $20.00High
2/1/2021UBS GroupInitiated CoverageNeutral$13.00Low
9/8/2020Jefferies Financial GroupInitiated CoverageBuy$21.00High
8/7/2020OppenheimerReiterated RatingBuyHigh
6/17/2020OppenheimerReiterated RatingBuy$22.00Medium
5/12/2020OppenheimerBoost TargetOutperform$16.00 ➝ $22.00High
3/25/2020Stifel NicolausInitiated CoverageBuy$19.00Low
2/27/2020BarclaysInitiated CoverageOverweight$22.00High
11/13/2019CowenReiterated RatingBuyHigh
8/13/2019CowenReiterated RatingBuyMedium
4/29/2019UBS GroupInitiated CoverageBuy ➝ Buy$12.00High
3/31/2019CowenReiterated RatingBuyLow
12/11/2018CIBCInitiated CoverageOutperform ➝ Outperform$15.00Medium
12/10/2018OppenheimerInitiated CoverageOutperform$15.00 ➝ $15.00High
12/10/2018LADENBURG THALM/SH SHReiterated RatingBuy$15.00High
11/20/2018CowenInitiated CoverageOutperformMedium
11/15/2018Evercore ISIInitiated CoverageOutperformHigh
10/8/2018LaidlawInitiated CoverageBuy ➝ Buy$18.00Medium
(Data available from 11/28/2017 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/2/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/1/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/1/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/31/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/30/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2022

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Molecular Templates logo
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Read More

Today's Range

Now: $0.60
Low: $0.60
High: $0.61

50 Day Range

MA: $0.64
Low: $0.56
High: $0.80

52 Week Range

Now: $0.60
Low: $0.54
High: $4.58

Volume

211 shs

Average Volume

195,983 shs

Market Capitalization

$33.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Molecular Templates?

The following equities research analysts have issued reports on Molecular Templates in the last twelve months: Bank of America Co., Barclays PLC, and Stifel Nicolaus.
View the latest analyst ratings for MTEM.

What is the current price target for Molecular Templates?

3 Wall Street analysts have set twelve-month price targets for Molecular Templates in the last year. Their average twelve-month price target is $3.83, suggesting a possible upside of 542.6%. Stifel Nicolaus has the highest price target set, predicting MTEM will reach $9.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $1.00 for Molecular Templates in the next year.
View the latest price targets for MTEM.

What is the current consensus analyst rating for Molecular Templates?

Molecular Templates currently has 1 sell rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MTEM, but not buy more shares or sell existing shares.
View the latest ratings for MTEM.

What other companies compete with Molecular Templates?

Other companies that are similar to Molecular Templates include Regulus Therapeutics, Clovis Oncology, Infinity Pharmaceuticals, Bolt Biotherapeutics and Catalyst Biosciences. Learn More about companies similar to Molecular Templates.

How do I contact Molecular Templates' investor relations team?

Molecular Templates' physical mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company's listed phone number is (512) 869-1555 and its investor relations email address is [email protected] The official website for Molecular Templates is www.mtem.com. Learn More about contacing Molecular Templates investor relations.